Dr. Reddy's Laboratories Q2 FY17 Press Presentation 2016

Dr. Reddy's Laboratories reports Q2 FY17 results with sequential growth across key markets, progress in quality remediation, completion of TEVA product portfolio acquisition, and continued R&D development on in-licensed proprietary assets from Xenoport and Eisai.